ICON’s Price Target Slashed 56% to $100 on Accounting Probe
Rothschild & Co Redburn analyst Jamie Clark cut ICON’s price target by 56% to $100 and downgraded to Neutral after an internal probe flagged potential FY2023-24 revenue overstatements. On January 9, Mizuho Securities trimmed its target to $216 but maintained Outperform, citing decelerating Q4 healthcare utilization.
1. Rothschild & Co Redburn Downgrade
On February 17, Rothschild & Co Redburn analyst Jamie Clark reduced ICON’s price target from $226 to $100 and downgraded the rating from Buy to Neutral after assessing emerging risks tied to an ongoing internal investigation.
2. Internal Accounting Probe
The company initiated an internal accounting investigation that has flagged preliminary findings of potential revenue overstatements for fiscal years 2023 and 2024, prompting concerns about the accuracy of past earnings and future growth projections.
3. Mizuho Securities Target Revision
Earlier on January 9, Mizuho Securities cut its price target from $225 to $216 while keeping an Outperform rating, noting decelerating healthcare utilization growth in Q4 based on its physician survey despite an easier year-over-year comparison.
4. CRO Business Model and Growth Drivers
ICON Public Limited Company operates as a contract research organization providing clinical trial management, development and commercialization services across biotech, pharmaceutical, public health and medical device clients, covering phases I through IV of clinical research.